Insider Buy at Neuronetics Signals Confidence Amid Volatility

Insider Buying at Neuronetics Signals Confidence Amid Volatility

The latest Form 4 filed by Chernett Jorey on 17 March 2026 shows a purchase of 531 000 shares of Neuronetics common stock at a weighted‑average price of $1.16—well below the current market price of $1.39. This buying activity occurs at a time when the stock has been on a steep decline, down nearly 73 % year‑to‑date, and has just entered a 52‑week low of $0.80. Jorey’s transaction, representing a modest 7 % increase in her holdings (from 6 985 404 to 7 516 404 shares), suggests a belief that the shares are undervalued and that the company’s new leadership and product pipeline will generate upside.

What Does This Mean for Investors?

Insider purchases are often interpreted as a positive signal, particularly when the insider is an early stakeholder or former executive. Jorey’s purchase—though small relative to her total holdings—occurs in the context of a broader wave of insider selling by top executives in February 2026, where both EVP William Macan and CEO Keith Sullivan sold large blocks at prices around $1.35‑$1.65. The contrast between insider buying by a non‑executive owner and selling by senior executives could indicate that Jorey sees a longer‑term upside that the current management may be under‑appreciating. For investors, this may warrant a closer look at the company’s recent strategic changes: a new CEO, a shelf registration allowing flexible capital raising, and a focus on chronic neuro‑health therapies that could open new revenue streams.

Profile of Chernett Jorey

Chernett Jorey has a long history of holding Neuronetics shares with occasional adjustments. Her most recent filing (Form 3) shows a baseline holding of 6 985 404 shares, with no recent trading activity aside from the March 17 purchase. Unlike the executive sales in early 2026, Jorey’s transactions have been limited and low‑profile, suggesting a passive investment stance that is now becoming more active. Historically, her trade volume has been modest, but the recent buy at $1.16—approximately 18 % below the market price—indicates a willingness to capitalize on perceived undervaluation. Her pattern of holding large blocks without frequent sales aligns with a long‑term investment strategy, reinforcing the view that she may be positioning for a potential rebound.

Implications for Neuronetics’ Future

The company’s recent filing of a Form S‑3 and the appointment of a new CEO signal a strategic shift toward growth and liquidity. With a market cap of roughly $88 million and a negative P/E of –1.44, Neuronetics remains in a distressed state but has recently announced a $20.7 million‑share shelf offering that could provide capital for research and development. The insider buying by Jorey, coupled with the social‑media buzz (≈51 % higher than average) and a slight positive sentiment shift, may hint at an emerging narrative that the company’s valuation is misaligned with its long‑term prospects. For investors, monitoring Jorey’s subsequent trades and the company’s financial performance post‑CEO transition will be crucial in assessing whether this insider confidence translates into tangible value creation.